10EE3CFC-9230-40BA-9C9F-77949BA763CC
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 4.0078843626806835
- age_years
- 42
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.502
- NOTCH_SIGNALING+0.418
- MYC_TARGETS_V1+0.402
- ADIPOGENESIS+0.320
- MTORC1_SIGNALING+0.319
- UV_RESPONSE_DN+0.299
- MITOTIC_SPINDLE+0.297
- TGF_BETA_SIGNALING+0.293
- UNFOLDED_PROTEIN_RESPONSE+0.269
- OXIDATIVE_PHOSPHORYLATION+0.268
Top 10 suppressed
- KRAS_SIGNALING_DN-0.405
- APICAL_SURFACE-0.279
- PANCREAS_BETA_CELLS-0.274
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.237
- TNFA_SIGNALING_VIA_NFKB-0.227
- MYOGENESIS-0.219
- APICAL_JUNCTION-0.166
- COAGULATION-0.149
- SPERMATOGENESIS-0.139
- HYPOXIA-0.131
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 0A7A28BA-9D46-4D4F-A0A5-B3F9AA8DF29B | — | — | 0.921 |
| 2 | MNG1038 | — | — | 0.896 |
| 3 | BE6A3670-34C4-4FD3-9794-C5B3254D9224 | — | — | 0.896 |
| 4 | 15824B66-5519-459A-B0C2-6EABAEEC2D8A | — | — | 0.890 |
| 5 | 63204446-7AA0-40DC-996D-440F4E19AD0F | — | — | 0.884 |
| 6 | SRR934762 | — | — | 0.879 |
| 7 | SRR934725 | — | — | 0.872 |
| 8 | 4099642A-F8D6-428C-AA12-1E76C27BB368 | — | — | 0.872 |
| 9 | AFCB278F-0EFB-4999-8D2C-C72B89A8403E | — | — | 0.872 |
| 10 | MNG328 | — | — | 0.863 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.502 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.418 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.402 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.320 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.319 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.299 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.297 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.293 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.269 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.268 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.267 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.255 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.253 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.250 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.240 | Temsirolimus | — uncovered |
| G2M_CHECKPOINT | 0.239 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.225 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.218 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.214 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.196 | Idelalisib | — uncovered |